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Abstract
The development of diabetic cardiomyopathy is a key contributor to heart failure and mortal-
ity in obesity and type 2 diabetes (T2D). Current therapeutic interventions for T2D have lim-
ited impact on the development of diabetic cardiomyopathy. Clearly, new therapies are
urgently needed. A potential therapeutic target is protein kinase D (PKD), which is activated
by metabolic insults and implicated in the regulation of cardiac metabolism, contractility and
hypertrophy. We therefore hypothesised that PKD inhibition would enhance cardiac func-
tion in T2D mice. We first validated the obese and T2D db/dbmouse as a model of early
stage diabetic cardiomyopathy, which was characterised by both diastolic and systolic dys-
function, without overt alterations in left ventricular morphology. These functional character-
istics were also associated with increased PKD2 phosphorylation in the fed state and a
gene expression signature characteristic of PKD activation. Acute administration of the
PKD inhibitor CID755673 to normal mice reduced both PKD1 and 2 phosphorylation in a
time and dose-dependent manner. Chronic CID755673 administration to T2D db/dbmice
for two weeks reduced expression of the gene expression signature of PKD activation, en-
hanced indices of both diastolic and systolic left ventricular function and was associated
with reduced heart weight. These alterations in cardiac function were independent of
changes in glucose homeostasis, insulin action and body composition. These findings sug-
gest that PKD inhibition could be an effective strategy to enhance heart function in obese
and diabetic patients and provide an impetus for further mechanistic investigations into the
role of PKD in diabetic cardiomyopathy.
Introduction
Obesity and type 2 diabetes (T2D) are associated with the development of heart failure, which
accounts for ~65% of deaths in obese and diabetic patients, based on US statistics [1]. Diabetic
cardiomyopathy describes abnormalities in cardiac metabolism that impair contractile func-
tion and induce pathological ventricular hypertrophy [2]. The early stages of diabetic cardio-
myopathy are characterised by impaired cardiac metabolism, which include insulin resistance,
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reduced glucose oxidation and increased lipid oxidation [3]. These metabolic alterations result
in an energetic deficit that first manifests as diastolic dysfunction, before progressing to systolic
dysfunction, and later hypertrophy and heart failure [4]. Existing therapeutics for T2D have
limited impact on preventing the development of diabetic cardiomyopathy and some even ag-
gravate the condition [5,6]. Therefore, new therapies that effectively combat the development
of diabetic cardiomyopathy are urgently needed.
Protein kinase D (PKD) is activated by metabolic abnormalities, neuroendocrine factors
and oxidative stress that are associated with obesity and T2D [7]. It is a serine/threonine kinase
with three known isoforms; PKD1–3 [7]. Previously thought to be a Protein kinase C (PKC)
isoform termed PKCμ, catalytic domain homology has since distinguished PKD as a member
of the calcium calmodulin-dependent kinase (CaMK) family [7]. Activation of PKD involves
binding of diacylglycerol to N-terminal cysteine rich domains that relieves autoinhibition of
the catalytic domain [8]. Phosphorylation of PKD at a number of sites within the C-terminal
catalytic domain confers full PKD activation, culminating in serine 916 autophosphorylation
[9]. Numerous growth factors, neuroendocrine factors and oxidative stress are all potent acti-
vators of PKD activity [7]. A number of studies have showed that metabolic abnormalities as-
sociated with obesity and T2D increase PKD activity. Indeed, PKD activation is increased in
cardiomycoytes co-treated with the saturated fatty acid palmitate and high glucose [10]. Similar
data is observed in the hearts of male Wistar rats exhibiting hyperglycemia in response to acute
(1 day) and chronic (7 day) streptozotocin treatment [10]. In addition, neurohormonal signal-
ling associated with obesity/T2D, such as endothelin-1 and norepinephrine, has also been
shown to activate PKD in vitro [11]. Changes in PKD activity are also dynamic and regulated
in a spatiotemporal manner [11], meaning that quantification of PKD activity in chronic dis-
ease states in vivo can be challenging. PKD is known to target a number of substrates in cardio-
myocytes, including the class IIa histone deacetylases (HDACs) [12] and cardiac troponin I
(cTnI) [13], to regulate processes such as metabolism [14], contractility [13] and hypertrophy
[12]. Together, these data suggest that PKD could be an effective target for pharmacological
modulation in diabetic cardiomyopathy.
A number of small molecule compounds with inhibitory action against PKD have been dis-
covered and synthesised. Of these, the benzoxoloazepinolone family of compounds have high
relative potency and specificity against PKD isoforms. The parent benzoxoloazepinolone,
termed CID755673, has IC50 values of 180, 280 and 227nM against PKD1–3 respectively, and
shows ~1000 fold selectivity over closely related PKC kinases [15]. Importantly and unlike
many other kinase inhibitors, this compound acts independently of the kinase ATP-binding
domain [15], which potentially explains its high degree of specificity. This compound inhibits
PKD-regulated processes, including class IIa HDAC phosphorylation [15], and has been used
to inhibit prostate cancer growth and motility [16] and pancreatitis in vivo [17] in a PKD-de-
pendent manner. The aim of this study was to determine whether the PKD inhibitor
CID755673 could prevent cardiac dysfunction in T2D db/dbmice. Here we report that T2D
db/dbmice are a model of early stage diabetic cardiomyopathy, characterised by both diastolic
and systolic dysfunction, without overt alterations in left ventricular morphology, which was
associated with elevated PKD2 auto phosphorylation in the fed state and a gene expression sig-
nature characteristic of PKD activation. Administration of the PKD inhibitor CID755673 to
T2D db/dbmice for two weeks enhanced indices of both diastolic and systolic left ventricular
function and was associated with reduced heart weight. These data suggest that PKD inhibition
could be an effective strategy to enhance cardiac function in obese and T2D patients.
CID755673 Administration in Diabetic Cardiomyopathy
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Materials and Methods
Animal experiments
This study was carried out in strict accordance with animal care guidelines stipulated by the
National Health and Medical Research Council (NHMRC) of Australia. The project was ap-
proved by the Deakin University Animal Ethics Committee (Application Number G09-2012).
All efforts were made throughout the study to minimise animal suffering. Male wild type
C57BL6, C57BL6J T2D db/db and control heterozygous (db/-) mice were obtained from the
Animal Resource Centre (Perth, Western Australia) and housed under constant temperature
and humidity with 12 h light-dark cycles, with free access to water and food. Untreated db/-
and db/dbmice underwent cardiac function assessment at 8 weeks of age and were killed two
days later in the fed or fasted state and the heart and right tibia were collected for later analysis.
For acute inhibitor studies, C57BL6 mice were administered a single dose of vehicle (5%
DMSO in PBS, pH 7.4), or the selective PKD inhibitor CID755673 at 1 or 10mg/kg body
weight. Mice were killed one or four hr later and heart collected for later analysis. For chronic
inhibitor experiments, 8-week old db/dbmice received vehicle or CID755673 at 1 or 10mg/kg
bodyweight for 16 days, by daily intraperitoneal (i.p.) injection. Body composition by EchoMRI
and insulin tolerance was assessed after 12 days of treatment. Insulin tolerance in db/dbmice
was assessed following a 4hr fast by measuring blood glucose obtained from the tail prior to,
and 20, 40, 60, 90 and 120 min after insulin (3.5U/kg) administration by i.p. injection. Cardiac
function was assessed after 14 days of treatment. At least 2 days later, mice were killed and 4hr
fasted blood glucose, the heart and right tibia were collected for later analysis.
Echocardiography
Echocardiography was performed on mice (n = 7–8/group) under isoflurane inhalation anaes-
thesia using a Phillips HD15 diagnostic ultrasound system with 15MHz linear-array transduc-
er. Intraventricular septum and left ventricular (LV) posterior wall thicknesses and LV
chamber dimensions during both diastole and systole were assessed in M-mode. Doppler imag-
ing provided indices of LV filling, aortic flow and ejection times. Fractional shortening (FS)
and ejection fraction, were derived from the M-mode measurements. LV mass was estimated
using M-mode data according to the equation by Troy [18], where estimated LV mass = 1.05
([LVIDD + LVPWD + IVSD]3- [LVIDD]3), where LVIDD is LV internal diameter at diastole,
LVPWD is LV posterior wall thickness at diastole and IVSD is intraventricular septum thick-
ness at diastole.
Tibia length measurement
Hind legs were covered with 1M NaOH and incubated at 37°C for 5 hours to digest skin, fat
and muscle. The tubes were gently agitated every 30 minutes to help aid digestion. After diges-
tion, the kneecap was carefully removed with forceps, and the tibia collected, rinsed, and then
dried on paper towel briefly. Tibia length (TL) was then measured using a vernier calliper and
used to normalise heart weights.
Histology
Hearts (n = 3) were rinsed with cold PBS, trimmed and the mid-sections fixed in 10% formalin.
Fixed hearts were paraffin embedded, sectioned (4μm thick) then stained with haematoxylin
and eosin (H&E). Stained tissue was imaged by light microscopy at 400x magnification and
analysed with Zeiss AxioVision software. The size of approximately two hundred cells per LV
were measured from 4–6 different fields to assess cardiomyocyte size.
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Western blotting
Heart ventricles (n = 3/group for acute inhibitor studies and n = 7–8/group for all other analy-
ses) were homogenised in ice-cold lysis buffer (50mM Tris pH7.5, 1mM EDTA, 1mM EGTA,
10% glycerol, 1% triton X-100, 50mM NaF, 5mMNa4P2O7, 1mMNa3VO4, 1mM DTT, prote-
ase inhibitor cocktail) and protein content was determined using the BCA method. 30μg of
protein was separated by SDS-PAGE and transferred onto PVDF membrane using standard
protocols. Blocked membranes were exposed to primary antibodies towards total PKD, pS916
PKD, total cTn1, pS23/24 cTnI, total HDAC5 (Cell Signalling Technology, Danvers, USA),
pS498 HDAC [19] and α-tubulin (Sigma-Aldrich, St. Louis, USA). Membranes were visualised
using the ChemiDoc XRS+ with Image Lab software. Band intensities of all samples were nor-
malised to an internal control sample that was included on each gel.
Real time RT-PCR
Heart ventricles (n = 7–8/group) were homogenised in trizol and RNA was isolated using
RNeasy columns (Qiagen, Doncaster, Australia). RNA was reverse transcribed using Super-
script III chemistry (Life Technologies, Mulgrave, Australia) and cDNA was quantified using
Oligreen (Life Technologies, Mulgrave, Australia). Real time RT-PCR was performed using
primers specific for Cox7a, PPARα, CPT-1b, PGC-1α, PDK4, GLUT4 and β-actin (sequences
published in reference [14]). Gene expression was quantified using the 2ΔCT method and nor-
malisation to β-actin expression, which was not different between groups (S1 and S2 Figs).
Statistical analyses
All data were analysed using unpaired t-tests or one-way analysis of variance with Tukey’s
post-hoc, using GraphPad Prism version 6.0 (Graph-Pad Software Inc., San Diego, USA) and
p< 0.05 was considered statistically significant. All data are reported as mean + standard error
of the mean (SEM).
Results
db/dbmice displayed impaired cardiac function
The db/dbmouse model of T2D is a validated model of diabetic cardiomyopathy [20], however
the exact phenotype and stage of disease at a given age can be dependent on strain background
and other colony specific factors [21]. We therefore evaluated disease progression in 8-week
old db/db C57BL6J mice through cardiac morphology and function assessment by echocardi-
ography. Compared with control db/-mice, db/dbmice had increased body weight and fasting
blood glucose (Fig. 1A), consistent with their T2D phenotype. There was no difference in heart
rate, or gross heart weight between db/- and db/dbmice (Fig. 1A). Normalised heart weight to
body weight and tibia length were different in db/dbmice, due to increased body weight and re-
duced tibia length in these mice (Fig. 1A). Echocardiographic assessment of heart structure
and function by M-mode and Doppler imaging (Fig. 1B) showed that LV structural dimensions
were similar, except that db/dbmice had thicker intraventricular septum at diastole and thinner
LV posterior wall at systole (Fig. 1C). Diastolic dysfunction was evident in db/dbmice, charac-
terised by a reduced E:A ratio (Fig. 1D) and increased deceleration time (Fig. 1E). No histologi-
cal evidence of fibrosis was observed (data not shown). An increased ejection time (Fig. 1F),
reduced ejection fraction (Fig. 1G) and decreased fractional shortening (Fig. 1H) also indicated
systolic dysfunction in these mice. These data validate the 8-week old db/dbmouse as a model
of developing cardiomyopathy characterised by diastolic and systolic dysfunction, but not
pathological hypertrophy.
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db/dbmice have increased PKD2 autophosphorylation in the fed state
and display a gene expression signature consistent with cardiac PKD
activation
We next assessed ventricular PKD activation in these mice. As PKD activation is sensitive to
nutrient availability [10], this was done in mice in the fed and fasted state. No difference was
found in autophosphorylation of full length PKD1 at S916 (Fig. 2A and B), which is indicative
of PKD activity [22], but we did observe an increase in full length PKD2 autophosphorylation
at S916 in fed db/dbmice (Fig. 2A and C). However, no differences in the phosphorylation of
target motifs within the PKD substrates cTn1 and HDAC5 were detected (Fig. 2D, E and F). As
Fig 1. Cardiac dysfunction in db/dbmice. (A) Physiological and cardiac morphological measures; (B) Representative M-mode and Doppler images; (C)
LV Structural dimensions; (D) E:A ratio; (E) Deceleration time; (F) Ejection time; (G) Ejection fraction, and; (H) Fractional shortening in db/- and db/dbmice.
Data represented are mean ± SEM, n = 7–8/group. * Denotes significantly different from db/-mice (p<0.05). IVS—intraventricular septum thickness; LVID—
left ventricular internal diameter; LVPW—left ventricular posterior wall thickness.
doi:10.1371/journal.pone.0120934.g001
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PKD activity is regulated in a spatiotemporal and dynamic manner [11], measurement of static
PKD autophosphorylation and PKD substrate phosphorylation might not be indicative PKD
activation patterns in vivo. We therefore examined a gene expression signature indicative of
chronic PKD activation in myocytes [14] as a more persistent measure of PKD activation. The
expression of 4 out of 6 PKD-dependent genes was elevated in fasted db/dbmice (Fig. 2G and
S1 Fig.). These data suggest that the diastolic and systolic dysfunction observed in db/dbmice
is associated with increased PKD2 activity in the fed state and a gene expression signature con-
sistent with elevated PKD activation.
Fig 2. Assessment of PKD activation in db/dbmice. (A) Representative western blots; (B) S916 PKD1 phosphorylation; (C) S916 PKD2 phosphorylation;
(D) Representative western blots; (E) S23/24 cTn1 phosphorylation; (F) S498 HDAC5 phosphorylation in db/- and db/dbmice in the fed or 4 hr fasted state,
and; (G) Heat map of a PKD- dependent gene expression signature in 4 hr fasted db/dbmice. Expression values are relative to db/-mice. Data represented
are mean ± SEM, n = 7–8/group.
doi:10.1371/journal.pone.0120934.g002
CID755673 Administration in Diabetic Cardiomyopathy
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The PKD inhibitor CID755673 reduces PKD activation in a time and
dose-dependent manner in C57BL6 mice
To determine whether CID755673 reduces PKD activity in the heart, wild type C57BL6 mice
were administered vehicle (5% DMSO in PBS) or CID755673 at 1 or 10mg/kg body weight,
and were killed 1 and 4 hr after drug administration. One hr after administration, CID755673
reduced PKD1 S916 autophosphorylation at both 1 and 10mg/kg (Fig. 3A and B), while there
was no effect on PKD2 (Fig. 3A and C). Four hr after administration, CID755673 had no effect
on PKD1 S916 autophosphorylation (Fig. 3D and E), while the 10mg/kg dose reduced PKD2
S916 autophosphorylation (Fig. 3D and F). These data show that .i.p. administered CID755673
reduced PKD activity in a time and dose-dependent manner.
Fig 3. Acute CID755673 administration reduces PKD activity in a time and dose-dependent manner. (A) Representative western blots; (B) S916 PKD1
phosphorylation; (C) S916 PKD2 phosphorylation in the ventricles of wild type C57BL6 mice 1 hr after drug administration. (D) Representative western blots;
(E) S916 PKD1 phosphorylation; (F) S916 PKD2 phosphorylation in the ventricles of wild type C57BL6 mice 4 hr after drug administration. Data represented
are mean ± SEM, n = 3/group. * Denotes significantly different from vehicle-treated mice (p<0.05).
doi:10.1371/journal.pone.0120934.g003
CID755673 Administration in Diabetic Cardiomyopathy
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The PKD inhibitor CID755673 enhanced left ventricular function in db/db
mice
db/dbmice were administered vehicle or CID755673 at 1 or 10mg/kg body weight by daily i.p.
injection for two weeks. CID755673 had no effect on body weight or fasting blood glucose, but
did induce a dose-dependent decrease in gross heart weight and heart weight when normalised
to tibia length (Fig. 4A). CID755673 administered at 10mg/kg increased heart rate when com-
pared with vehicle (Fig. 4A). Echocardiographic assessment of heart structure and function by
M-mode and Doppler imaging (Fig. 4B) showed that CID755673 administration at 10mg/kg
reduced LV posterior wall (LVPW) thickness at diastole when compared with both vehicle and
1mg/kg CID755673 administration regimens (Fig. 4C). CID755673 administered at both doses
reduced LV internal diameter (LVID) at systole. No other differences in LV morphology at ei-
ther diastole or systole were observed with CID755673 administration. However, CID755673
administration at 10mg/kg enhanced both diastolic function, signified by an increased E:A
ratio (Fig. 4D) and reduced deceleration time (Fig. 4E), and systolic function, demonstrated by
decreased ejection time (Fig. 4F). Dose-dependent increases in indices of systolic function,
such as ejection fraction (Fig. 4G) and fractional shortening (Fig. 4H) were also observed. To-
gether, these data show that the PKD inhibitor CID755673 enhanced both diastolic and systolic
cardiac function in db/dbmice, which was associated with a reduction in gross heart weight
and reduced LVID at systole.
CID755673 administration was associated with an altered PKD-
dependent gene expression signature, consistent with PKD inhibition
We next assessed PKD-dependent signalling in the ventricles of vehicle and CID755673-
treated mice that had undergone a 4hr fast (Fig. 4A). We first assessed whether CID755673 ad-
ministration altered our PKD-dependent gene expression signature. The expression of 4 PKD-
dependent genes was reduced by CID755673 administration across both doses, suggestive of
PKD inhibition, while the remaining 2 genes were markedly increased (Fig. 5A and S2 Fig.).
No differences in S23/S24 cTn1 (Fig. 5B and C) and S498 HDAC5 (Fig. 5B and D) phosphory-
lation was observed with CID755673 administration. However, we did observe a significant in-
crease in the expression of the KCNH2 gene (Fig. 5E), which encodes a potassium voltage-
gated channel involved in cardiomyocytes electrical function that is thought to be suppressed
by PKD in obesity [23]. Together, these data suggest some impairment in downstream PKD
signalling in CID755673 treated db/dbmice.
CID755673-mediated reduction in heart size was not specific for the LV
We further assessed the cardiac remodelling that contributed to the reduced heart size and en-
hanced cardiac function observed following CID755673 administration. To examine the specif-
ic effects on heart morphology, we examined LV cell size by histology (Fig. 6A). CID755673
administration at 10mg/kg reduced LV cell size (Fig. 6A), and calculated LV mass fromM-
mode echocardiography was reduced at both drug doses (Fig. 6B). However calculated LV
mass was not different when normalised to total heart weight (Fig. 6C), suggesting that the re-
duction in heart weight was consistent across all chambers of the heart. These alterations could
not be ascribed to changes in body composition or insulin tolerance (S3 Fig.), suggesting that
gross alterations in systemic metabolism were not involved. Together, these data show that the
PKD inhibitor CID755673 enhanced cardiac systolic and diastolic function in diabetic cardio-
myopathy in association with reduced heart size, but with only minor alterations in LV internal
structural dimensions.
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Fig 4. The PKD inhibitor CID755673 enhances cardiac function in db/dbmice. (A) Physiological and cardiac morphological measures; (B)
Representative M-mode and Doppler images; (C) LV Structural dimensions; (D) E:A ratio; (E) Deceleration time; (F) Ejection time; (G) Ejection fraction, and;
(H) Fractional shortening in db/dbmice treated with vehicle, 1mg/kg or 10mg/kg CID755673. Data represented are mean ± SEM, n = 7–8. † Denotes
significantly different from vehicle mice (p<0.05). # Denotes significantly different from 1mg/kg CID755673-treated mice. Veh—vehicle; IVS—intraventricular
septum thickness; LVID—left ventricular internal diameter; LVPW—left ventricular posterior wall thickness.
doi:10.1371/journal.pone.0120934.g004
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Discussion
Cardiovascular disease and heart failure are major comorbidities for T2D, accounting for
~65% of deaths due to T2D [1]. Clearly new therapeutic strategies are needed to attenuate the
incidence of cardiovascular disease mortality in obese and T2D patients, which would be most
effectively targeted in the early stages of diabetic cardiomyopathy development. Here we
showed that the obese and T2D db/dbmouse on a C57BL6J background at 8 weeks of age rep-
resents a model of developing diabetic cardiomyopathy characterised by systolic and diastolic
dysfunction, in the absence of compensatory pathological hypertrophy. Therefore, this mouse
model is useful for the study of developing diabetic cardiomyopathy and for experimental drug
Fig 5. Assessment of PKD activation in CID755673-treated db/dbmice. (A) Heat map of a PKD- dependent gene expression signature; (B)
Representative western blots; (C) S23/24 cTn1 phosphorylation; (D) S498 HDAC5 phosphorylation; (E) KCNH2 gene expression in vehicle, 1mg/kg and
10mg/kg CID755673-treated db/dbmice. Expression values are relative to db/-mice. Data represented are mean ± SEM, n = 7–8/group. *Denotes
significantly different from vehicle-treated mice (p<0.05).
doi:10.1371/journal.pone.0120934.g005
Fig 6. The CID755673-mediated reduction in heart size is not specific for the LV. (A) Representative cell size images and quantification; (B) Estimated
gross LV mass, and; (C) LV mass normalised to heart weight in db/dbmice treated with vehicle, 1mg/kg or 10mg/kg CID755673. Data represented are
mean ± SEM, n = 3–8/group. †Denotes significantly different from vehicle mice (p<0.05).
doi:10.1371/journal.pone.0120934.g006
CID755673 Administration in Diabetic Cardiomyopathy
PLOS ONE | DOI:10.1371/journal.pone.0120934 March 23, 2015 10 / 14
studies aimed at preventing the disease in its early stages. We observed increased PKD2 activa-
tion in the fed state in these db/dbmice and components of a gene expression signature of
PKD activation were elevated. Administration of the PKD inhibitor CID755673 to db/dbmice
for 2-weeks improved both systolic and diastolic cardiac function, and was associated with a re-
duction in gross heart size. Together, these data suggest that compounds with inhibitory activi-
ty towards PKD could be effective in enhancing cardiac function in diabetic cardiomyopathy,
when administered in the early stages of the disease.
The finding that PKD2 autophosphorylation was increased in db/dbmice in the fed state
provides further evidence that PKD isoforms are sensitive to alterations in substrate availabili-
ty. The finding that PKD2 activation was not different between control and db/dbmice after 4
hr of fasting is consistent with other observations showing that PKD activation is dynamic [24]
and can be regulated in a spatiotemporal manner [11]. It is possible that static measures of
PKD activity in whole ventricle lysates are not spatiotemporally sensitive enough to accurately
assess PKD activity in vivo. Therefore, we assessed a gene expression signature of PKD activa-
tion, which we previously identified in myocytes following constitutively active PKD expres-
sion [14], as a more stable measure of PKD activation in these hearts. Although consisting
primarily of metabolic genes, we observed that 4 of 6 genes of the expression signature were el-
evated in diabetic db/dbmice when compared with control mice. It should be noted that the 2
remaining genes, PDK4 and GLUT4, were substantially increased in response to CID755673.
However, it is possible that these genes were up-regulated by secondary mechanisms related to
alterations in glucose flux following the cardiac remodelling by CID755673. Clearly further re-
search will be required to more clearly define PKD activation patterns in the development of
diabetic cardiomyopathy in vivo, including any time course of activation and the putative fac-
tors contributing to any increases in PKD activity. An intriguing finding from this study was
that despite measures of PKD activation and the profound effects of CID755673 on cardiac
function in db/dbmice, we did not observe any alterations in the phosphorylation of two puta-
tive downstream PKD targets in these same mice. cTn1 and HDAC5 are both phosphorylated
by PKD and are thought to regulate contractility and hypertrophy and metabolism responses,
respectively. However, the effect of CID755673 on the cardiomyopathy observed in db/dbmice
could be due to the regulation of other, including as yet unidentified, PKD targets.
The underlying mechanisms by which CID755673 enhanced both diastolic and systolic
function are unknown. However, in the context of developing diabetic cardiomyopathy, PKD
is known to regulate both cardiac metabolism and contractility. Indeed, loss of PKD1 through
either siRNA or through genetic knockout is associated with a loss of GLUT4 translocation
and glucose uptake [25]. This is consistent with our own data in myocytes showing that consti-
tutive PKD activation enhances glucose oxidation [14]. However, as the development of diabet-
ic cardiomyopathy is associated with a shift from glucose to lipid metabolism, this would
suggest that PKD inhibition would be unlikely to result in restoration of glucose metabolism
that in turn prevents or reverses the diabetic cardiomyopathy phenotype. However, PKD has
also been linked to increased fatty acid uptake under insulin resistant conditions [26], suggest-
ing that impairment in PKD activity could contribute to cardiac lipotoxicity in insulin resis-
tance. An alternative mechanism by which CID755673 had its effects on diastolic and systolic
function could be through modulation of cardiac contractility. Indeed, heart rate was increased
in CID755673-treated animals, possibly indicating that contractile processes and/or calcium
handling were improved. While we did not see any difference in cTn1 phosphorylation in any
of our analyses, we did observe an increase in the expression of the KCNH2 gene, which en-
codes the Kv11.1 voltage-gated potassium channel that is required for normal cardiac electrical
conduction. PKD has been found to suppress this gene in obesity [23] and could be one mecha-
nism by which PKD inhibition enhanced both diastolic and systolic function. It should also be
CID755673 Administration in Diabetic Cardiomyopathy
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noted that PKD inhibition can be detrimental in settings of ischemia-reperfusion injury [27],
which suggests that the protective effects of CID755673 in db/dbmice are likely to be specific
to the disease itself.
Treatment of db/dbmice with CID755673 resulted in a dose dependent reduction in gross
heart size. Although this was associated with a reduction in LV cell size and estimated LV
mass, the reduction in mass was not specific for the LV as there was no change in LV mass
when normalised to heart weight. This is consistent with our initial characterisation of the db/
dbmodel that showed no pathological hypertrophy and suggests that a fundamental process
controlling cardiomyocyte size was affected by CID755673 treatment. Indeed, a recent report
suggests that PKD3 can directly phosphorylate and activate S6K1, in an mTOR-independent
manner, which contributes to breast cancer cell growth [28]. Whether this mechanism explains
the whole heart phenotype observed in the present study is unclear, however it should be noted
that the reduction in heart size was not associated with deleterious effects on heart function but
instead improvements in cardiac function. This could suggest that the reduction in heart
weight in CID755673-treated mice was related to decompensation due to enhanced function.
Indeed, the reduction in heart size and enhancement in cardiac function is remarkably similar
to that observed with loss of phospholamban in disease states [29].
In conclusion, here we showed that the 8 week old db/dbmouse is a model of developing di-
abetic cardiomyopathy characterised by diastolic and systolic dysfunction, but not pathological
hypertrophy, and PKD2 activation in the fed state. Diastolic and systolic function were en-
hanced following 2-weeks of treatment with the CID755673 PKD inhibitor and was associated
with a reduction in gross heart weight. Current first line treatments for T2D are typically fo-
cussed on controlling blood glucose levels, and have varying effects on diabetic cardiomyopa-
thy [5,30,31]. The remaining high prevalence of heart failure in obesity and T2D suggests that
additional therapeutic interventions are required. The proof-of-principle findings in the pres-
ent study suggest that small molecules that have inhibitory activity towards PKD could be
promising therapeutics to reduce heart disease in obese and diabetic patients. In addition to ge-
netic gain and loss of function studies to determine the exact role of PKD in diabetic cardiomy-
opathy, further toxicity and efficacy testing of other PKD inhibitors and long term drug studies
are warranted and could support a role for PKD inhibition as a therapeutic treatment option
for developing diabetic cardiomyopathy.
Supporting Information
S1 Fig. PKD-dependent gene expression in db/- and db/dbmice. (A) Cytochrome C oxidase
subunit 7a (Cox7a); (B) Peroxisome proliferator-activated receptor alpha (PPARα); (C) carni-
tine palmitoyltransferase 1b (CPT-1b); (D) PPAR gamma coactivator 1 alpha (PGC-1α); (E)
pyruvate dehydrogenase kinase isoform 4 (PDK4); (F) facilitative glucose transporter isoform 4
(GLUT4), and; (G) β-actin gene expression in control db/- and type 2 diabetic db/dbmice.
Gene expression levels in A-F were normalised to β-actin expression. Data are represented as
means ± SEM. Denotes significantly different from db/-mice (p<0.05).
(TIF)
S2 Fig. PKD-dependent gene expression in db/dbmice treated with vehicle, 1mg/kg or 10
mg/kg CID755673. (A) Cytochrome C oxidase subunit 7a (Cox7a); (B) Peroxisome prolifera-
tor-activated receptor alpha (PPARα); (C) carnitine palmitoyltransferase 1b (CPT-1b); (D)
PPAR gamma coactivator 1 alpha (PGC-1α); (E) pyruvate dehydrogenase kinase isoform 4
(PDK4); (F) facilitative glucose transporter isoform 4 (GLUT4), and; (G) β-actin gene expres-
sion in vehicle (Veh), 1mg/kg CID755673 and 10mg/kg CID755673 treated db/dbmice. Gene
expression levels in A-F were normalised to β-actin expression. Data are represented as
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means ± SEM. Denotes significantly different from vehicle treated mice (p<0.05).
(TIF)
S3 Fig. Metabolic and body composition measures in db/dbmice treated with vehicle, 1
mg/kg or 10 mg/kg CID755673. (A) Change (Δ) in blood glucose (mM) during an insulin tol-
erance test in vehicle, 1mg/kg CID755673 and 10mg/kg CID755673 treated db/dbmice. Mice
were administered 3.5U/kg insulin via intraperitoneal injection. (B) Body composition in vehi-
cle, 1mg/kg CID755673 and 10mg/kg CID755673 treated db/dbmice, assessed by EchoMRI.
Data are represented as mean ± SEM.
(TIF)
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